Alliance Pharmaceutical Corp. announces additional board member.SAN DIEGO--(BUSINESS WIRE)--Aug. 19, 1996--Alliance Pharmaceutical Corp. Monday announced that Pedro Cuatrecasas Pedro Cuatrecasas (1936) is an American biochemist and an Adjunct Professor of Pharmacology & Medicine at the University of California, San Diego.[1] Birth and education Pedro Cuatrecasas was born in 1936 in Madrid, Spain. He completed his A.B. , M.D., was elected to its board of directors at a directors meeting on Aug. 13, 1996. Cuatrecasas is presently vice president of Warner-Lambert Co. and president, pharmaceutical research, of Parke-Davis in Ann Arbor Ann Arbor, city (1990 pop. 109,592), seat of Washtenaw co., S Mich., on the Huron River; inc. 1851. It is a research and educational center, with a large number of government and industrial research and development firms, many in high-technology fields such as , Mich. Cuatrecasas has more than 20 years' experience in the pharmaceutical industry, having held executive positions in research and development at Burroughs Wellcome and Glaxo before joining Warner-Lambert in 1989. Prior to joining Burroughs Wellcome, he was a professor at the Johns Hopkins University School of Medicine The Johns Hopkins University School of Medicine, located in Baltimore, Maryland, USA, is a highly regarded medical school and biomedical research institute in the United States. . According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Duane Roth, chief executive officer of Alliance: "Dr. Cuatrecasas has a great deal of direct experience in the management of drug products through the regulatory approval process. We are pleased to add a person of his stature to our board." Alliance is a pharmaceutical research and development company with three products currently in clinical studies: Oxygent, an intravascular intravascular /in·tra·vas·cu·lar/ (in?trah-vas´ku-lar) within a vessel. in·tra·vas·cu·lar adj. Within one or more blood vessels. oxygen carrier for use as a temporary "blood substitute," which is being co-developed with affiliates of Johnson & Johnson; LiquiVent, an intrapulmonary "liquid ventilation" drug for use in treating patients with acute respiratory failure Respiratory Failure Definition Respiratory failure is nearly any condition that affects breathing function or the lungs themselves and can result in failure of the lungs to function properly. , which is being co-developed with Hoechst Marion Roussel; and Imagent US, an intravenous contrast agent for enhancement of ultrasound images. CONTACT: Alliance Pharmaceutical Corp., San Diego Gwen Rosenberg, 619/558-4300 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion